Benzinga | Jun 17, 2021 09:17AM EDT

HC Wainwright & Co. Upgrades Acorda Therapeutics to Buy, Raises Price Target to $10

HC Wainwright & Co. analyst Raghuram Selvaraju upgrades Acorda Therapeutics (NASDAQ:ACOR) from Neutral to Buy and raises the price target from $5 to $10.HC Wainwright & Co. analyst Raghuram Selvaraju upgrades Acorda Therapeutics (NASDAQ:ACOR) from Neutral to Buy and raises the price target from $5 to $10.